Arbel Leor T, Hsu Edmund, McNally Keegan
University of Central Florida College of Medicine.
Cureus. 2017 Aug 23;9(8):e1599. doi: 10.7759/cureus.1599.
Clostridium difficile () is a common cause of antibiotic--associated diarrhea (AAD), being responsible for 15--25% of all AAD cases. The purpose of this literature review is to determine the cost-effectiveness of fecal microbiota transplantation (FMT) and how it compares in this regard to the standard treatments of choice for recurrent C. difficile infection (CDI). The review of the literature along with the evaluation of three comparative cost effective analyses yielded findings consistent with the view that FMT is the most cost-effective option in treating recurrent CDI. There are some (but considerably less) data indicating that FMT may be a cost effective strategy in treating initial CDI, as well. The superior cost-effectiveness of FMT as compared to the preferred standards of treatment for recurrent CDI suggest FMT use should become more integrated in routine clinical practice. Increased utilization of FMTs would allow for better control of this increasingly problematic disease as well as lower costs associated with its management.
艰难梭菌是抗生素相关性腹泻（AAD）的常见病因，占所有AAD病例的15%-25%。本文献综述的目的是确定粪便微生物群移植（FMT）的成本效益，以及在这方面它与复发性艰难梭菌感染（CDI）的标准首选治疗方法相比如何。文献综述以及三项比较成本效益分析的评估结果一致表明，FMT是治疗复发性CDI最具成本效益的选择。有一些（但数量少得多）数据表明，FMT在治疗初始CDI方面也可能是一种具有成本效益的策略。与复发性CDI的首选治疗标准相比，FMT具有更高的成本效益，这表明FMT的使用应更多地融入常规临床实践。增加FMT的使用将有助于更好地控制这种日益棘手的疾病，并降低其管理成本。
